Why is the ResMed share price sinking again on Monday?

ResMed shares are having a very tough time this month.

| More on:
A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ResMed Inc. (ASX: RMD) share price is having another disappointing session on Monday.

In morning trade, the sleep treatment company's shares are down 6.5% to a 52-week low of $28.70.

This means that its shares are now down 15% over the last two trading sessions following the release of a weaker-than-expected quarterly update.

Why is the ResMed share price sinking again?

Investors have been hitting the sell button today after the company's NYSE-listed shares fell more than expected on Friday night.

Each ResMed share on the NYSE represents 10 on the ASX. This means they are inextricably linked and will usually move in tow with one another.

On Friday night, the ResMed share price fell 18% to US$179.88 (including after-hours trade). This equates to A$273.28 at current exchange rates, which suggests that fair value for its locally listed shares is now $27.33.

Is this a buying opportunity?

The team at Goldman Sachs believes investors should be snapping up shares following this selloff.

While the broker was disappointed with ResMed's update, it believes that the margin weakness, which caused the earnings miss, will soon improve. Goldman said:

FY23 gross margin of 56.5% remains -330bps below FY20 levels, with a sequential deterioration of 30bps from 3Q to 4Q the primary driver of a (5)% earnings miss today (sales growth of +23% was approximately double the 10-year average).

However, in the context of various unprecedented market dynamics, the factors suppressing GM are generally understandable and likely to improve: 1) ongoing competitor challenges skewing sales mix heavily to devices over masks/consumables; 2) elevated freight costs tapering down but more slowly than anticipated; 3) component/other input cost inflation proving stubborn.

In light of this, its analysts have retained their buy rating with a $38.40 price target.

Based on the current ResMed share price, this implies a potential upside of approximately 33% for investors over the next 12 months.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Guess which ASX 200 stock just jumped 9% on big news

Let's find out what is getting investors excited today.

Read more »